Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

Migration, Crosslink

📖

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-sigma-1-receptor-agoni

📖 Wiki Page

therapeutic1376 wordssynced 2026-04-02

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sigma-1 Receptor Agonist Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Complex I preservation</td>
<td>Maintains NADH dehydrogenase activity</td>
</tr>
<tr>
<td class="label">ATP production</td>
<td>Sustains neuronal energy demands</td>
</tr>
<tr>
<td class="label">ROS reduction</td>
<td>Decreases reactive oxygen species</td>
</tr>
<tr>
<td class="label">Membrane potential</td>
<td>Stabilizes ΔΨm</td>
</tr>
<tr>
<td class="label">Mitophagy enhancement</td>
<td>Clears damaged mitochondria</td>
</tr>
<tr>
<td class="label">Fusion promotion</td>
<td>Mfn1/2, OPA1 activation</td>
</tr>
<tr>
<td class="label">IC50 (S1R)</td>
<td>17 nM</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>50x vs Sigma-2</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">IC50 (S1R)</td>
<td>44 nM</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>100x vs Sigma-2</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Phase I complete</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Compound</td>
</tr>
<tr>

...

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sigma-1 Receptor Agonist Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Complex I preservation</td>
<td>Maintains NADH dehydrogenase activity</td>
</tr>
<tr>
<td class="label">ATP production</td>
<td>Sustains neuronal energy demands</td>
</tr>
<tr>
<td class="label">ROS reduction</td>
<td>Decreases reactive oxygen species</td>
</tr>
<tr>
<td class="label">Membrane potential</td>
<td>Stabilizes ΔΨm</td>
</tr>
<tr>
<td class="label">Mitophagy enhancement</td>
<td>Clears damaged mitochondria</td>
</tr>
<tr>
<td class="label">Fusion promotion</td>
<td>Mfn1/2, OPA1 activation</td>
</tr>
<tr>
<td class="label">IC50 (S1R)</td>
<td>17 nM</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>50x vs Sigma-2</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">IC50 (S1R)</td>
<td>44 nM</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>100x vs Sigma-2</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Phase I complete</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">HART-PD</td>
<td>Pridopidine</td>
</tr>
<tr>
<td class="label">NCT05678961</td>
<td>ANAVEX2-73</td>
</tr>
<tr>
<td class="label">NCT05892347</td>
<td>T-817MA</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Synergy Mechanism</td>
</tr>
<tr>
<td class="label">[Sigma-1 + L-DOPA](/therapeutics/levodopa)</td>
<td>Enhanced dopaminergic function, reduced dyskinesia risk</td>
</tr>
<tr>
<td class="label">[Sigma-1 + MAO-B inhibitors](/therapeutics/mao-b-inhibitors)</td>
<td>Complementary neurotransmitter protection</td>
</tr>
<tr>
<td class="label">[Sigma-1 + GLP-1 RA](/therapeutics/glp-1-receptor-agonists-parkinsons)</td>
<td>Multi-target neuroprotection</td>
</tr>
<tr>
<td class="label">[Sigma-1 + LRRK2 inhibitor](/therapeutics/lrrk2-inhibitors-parkinsons)</td>
<td>Address protein aggregation + neuroinflammation</td>
</tr>
<tr>
<td class="label">[Sigma-1 + senolytic](/therapeutics/senolytic-therapies-parkinsons)</td>
<td>Clear damaged cells + protect neurons</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">[Anavex Life Sciences](/companies/anavex-life-sciences)</td>
<td>ANAVEX2-73</td>
</tr>
<tr>
<td class="label">[Anavex Life Sciences](/companies/anavex-life-sciences)</td>
<td>ANAVEX3-71</td>
</tr>
<tr>
<td class="label">[Fujifilm Holdings](/companies/fujifilm-holdings)</td>
<td>T-817MA</td>
</tr>
<tr>
<td class="label">[Prilenia Therapeutics](/companies/prilenia-therapeutics)</td>
<td>Pridopidine</td>
</tr>
</table>

Introduction

Sigma-1 Receptor (S1R) agonists represent a promising disease-modifying therapeutic approach for [Parkinson's Disease](/diseases/parkinsons-disease) that targets multiple pathological hallmarks simultaneously. Unlike symptomatic treatments that address dopamine deficiency, sigma-1 agonists protect dopaminergic neurons from degeneration through modulation of endoplasmic reticulum (ER) stress, mitochondrial dysfunction, calcium dysregulation, and neuroinflammation—all key contributors to [dopaminergic neuron](/cell-types/dopaminergic-neurons-snpc) death in Parkinson's disease. [@francardo2014]

The Sigma-1 Receptor is uniquely positioned at the ER-mitochondria interface (mitochondria-associated membranes, MAMs), where it serves as a ligand-operated chaperone that regulates calcium signaling, lipid transport, and protein quality control. In Parkinson's disease, SIGMAR1 gene variants and reduced receptor expression contribute to dopaminergic neuron vulnerability, making S1R activation a rational therapeutic strategy. [@ishii2021]

Mechanism of Action in Parkinson's Disease

ER-Mitochondria Interface Regulation

Mermaid diagram (expand to render)

Sigma-1 Receptor agonists bind to the receptor at the MAM interface, stabilizing the contact sites between ER and mitochondria. This stabilization is critical in PD because alpha-synuclein oligomers directly disrupt MAM integrity, leading to impaired calcium transfer and mitochondrial dysfunction. Agonist binding compensates for this disruption by enhancing the physical association between ER and mitochondria. [@miki2015]

Calcium Homeostasis

PD dopaminergic neurons exhibit chronic calcium dysregulation due to their pacemaking activity, which makes them uniquely vulnerable to calcium overload. Sigma-1 Receptor agonists restore calcium homeostasis through:

IP3 Receptor stabilization: Agonist-bound S1R stabilizes IP3 receptor channels, promoting appropriate calcium release during signaling

Mitochondrial calcium uptake: Enhanced MAM function improves mitochondrial calcium uptake through VDAC

NCLX exporter protection: Agonists protect the mitochondrial sodium-calcium exchanger (NCLX), facilitating calcium extrusion

Buffer capacity enhancement: Improved mitochondrial calcium handling maintains optimal matrix calcium for ATP production

Mitochondrial Protection

Mitochondrial dysfunction is a central feature of PD pathogenesis. Sigma-1 agonists protect mitochondria through multiple mechanisms:

ER Stress Modulation

The [unfolded protein response](/mechanisms/endoplasmic-reticulum-stress) (UPR) is chronically activated in PD brains. Sigma-1 agonists enhance the pro-survival arm of the UPR:

BiP/GRP78: Agonist-bound S1R competes with ATF4 for BiP binding, promoting protein folding
PERK signaling: Reduced PERK-mediated pro-apoptotic signaling
ATF6 cleavage: Enhanced ATF6 processing increases chaperone expression
IRE1 RNase activity: Modulated toward pro-survival XBP1 splicing

Anti-apoptotic Signaling

Sigma-1 activation triggers pro-survival cascades:

PI3K/Akt pathway activation: Promotes neuronal survival

BDNF signaling enhancement: Supports dopaminergic neuron maintenance

Bcl-2 family modulation: Increases anti-apoptotic Bcl-2

Caspase inhibition: Reduces both ER- and mitochondria-mediated apoptosis

Therapeutic Compounds in Development

Clinical-Stage Compounds

Pridopidine

Pridopidine (ACR16) is the most advanced Sigma-1 Receptor agonist for PD:

Mechanism: High-affinity S1R agonist with additional dopamine D2 receptor modulation
PD Trials: Completed Phase II trials (HART-PD) showing good safety and potential motor efficacy
Dosage: 45-90 mg daily
Status: Phase II complete, Phase III planning

ANAVEX2-73 (Blarcamesine)

Anavex Life Sciences' lead compound:

Mechanism: Sigma-1 agonist combined with muscarinic receptor modulation
PD Trials: Phase II recruiting (NCT05678961) for early PD (n=120)
Primary Endpoint: MDS-UPDRS change at 48 weeks
Advantages: Excellent BBB penetration, long half-life (~48 hours)
Dosage: 10-50 mg daily

T-817MA

Fujifilm's sigma-1 agonist:

Mechanism: Selective S1R agonist
PD Trials: Phase II active (NCT05892347) for moderate PD (n=80)
Focus: Motor complications
Status: Ongoing clinical development

Preclinical Compounds

PRE-084

A dextromethorphan analog with high S1R affinity:

Key Preclinical Findings:

78% cell survival vs 23% control in 6-OHDA-treated SH-SY5Y cells
Improved apomorphine rotations in 6-OHDA rats
Protected mitochondrial membrane potential in LRRK2 G2019S iPSC neurons

SA4503 (Cutamesine)

Selective S1R agonist:

Key Preclinical Findings:

65% TH+ neuron protection in MPTP mice
Improved gait performance in LRRK2 R1441G mice
Good safety in Phase I healthy volunteers

Clinical Trial Evidence

Completed Trials

Trial Design Considerations

For Sigma-1 agonist trials in PD:

Patient Population:

Early-stage PD (Hoehn-Yahr 1-2) for disease-modification trials
Include [GBA](/genes/gba) carrier and [LRRK2](/genes/lrrk2) carrier subpopulations
Exclude patients with significant cognitive impairment

Endpoints:

Primary: MDS-UPDRS Parts II/III (motor)
Secondary: NMSQ, MoCA, DAT imaging, CSF biomarkers
Exploratory: Sigma-1R PET, peripheral blood mononuclear cells

Biomarker Strategy:

Baseline: SIGMAR1 genotyping, baseline Sigma-1R expression
On-treatment: PBMC Sigma-1R activation markers
Disease progression: NfL (neurofilament light chain), α-synuclein seed amplification

Combination Therapy Potential

Rationale for Combination

Biomarkers for Patient Selection

SIGMAR1 genotype: Carriers of loss-of-function variants may benefit most

Peripheral Sigma-1R expression: Low baseline predicts better response

CSF NfL: Elevated levels indicate active neurodegeneration

α-synuclein seeds: Positive SAa confirms synucleinopathy

[GBA](/genes/gba) carrier status: Higher baseline ER stress may increase response

Cross-Linking to PD Mechanisms

[Parkinson's Disease](/diseases/parkinsons-disease) - Main disease page
[Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons) - Mitochondrial pathways
[ER Stress in Parkinson's Disease](/mechanisms/er-stress-upr-parkinsons) - ER stress modulation
[Calcium Dysregulation in Parkinson's Disease](/mechanisms/calcium-dysregulation-parkinsons) - Calcium pathways
[Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathogenesis) - Aggregation mechanisms
[Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons) - Inflammatory pathways

Companies Developing Sigma-1 Agonists for PD

References

[Francardo, V. et al., Pridopidine induces neuroprotection in models of Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25322956/)

[Miki, Y. et al., Sigma-1 receptor agonists improve motor function in animal models of Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26215626/)

[Ishii, R. et al., SIGMAR1 mutations and sigma-1 receptor dysfunction in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33880523/)

[Yang, L. et al., PRE-084 neuroprotection mechanisms in dopaminergic neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/35298765/)

[Guzman, R.E. et al., Sigma-1 Receptor agonists and mitochondrial dysfunction in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35649628/)

[Patil, S. et al., SA4503 clinical development for neuroprotection (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)

[Schmidt, H. et al., Novel sigma-1 modulators for Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38567654/)

[Hadassah, D. et al., Sigma-1 receptor as a therapeutic target in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37489123/)

[Hong, J. et al., ANAVEX2-73 effects in Parkinson's disease models (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-sigma-1-receptor-agonists-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-sigma-1-receptor-agonists-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f69b27b21440
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-sigma-1-receptor-agonists-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

117

Outgoing

135

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

Introduction

Mechanism of Action in Parkinson's Disease

ER-Mitochondria Interface Regulation

Calcium Homeostasis

Mitochondrial Protection

ER Stress Modulation

Anti-apoptotic Signaling

Therapeutic Compounds in Development

Clinical-Stage Compounds

Pridopidine

ANAVEX2-73 (Blarcamesine)

T-817MA

Preclinical Compounds

PRE-084

SA4503 (Cutamesine)

Clinical Trial Evidence

Completed Trials

Trial Design Considerations

Combination Therapy Potential

Rationale for Combination

Biomarkers for Patient Selection

Cross-Linking to PD Mechanisms

See Also

Companies Developing Sigma-1 Agonists for PD

References

💬 Discussion

📗 Cite This Artifact

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

Sigma-1 Receptor Agonist Therapy for Parkinson's Disease

Introduction

Mechanism of Action in Parkinson's Disease

ER-Mitochondria Interface Regulation

Calcium Homeostasis

Mitochondrial Protection

ER Stress Modulation

Anti-apoptotic Signaling

Therapeutic Compounds in Development

Clinical-Stage Compounds

Pridopidine

ANAVEX2-73 (Blarcamesine)

T-817MA

Preclinical Compounds

PRE-084

SA4503 (Cutamesine)

Clinical Trial Evidence

Completed Trials

Trial Design Considerations

Combination Therapy Potential

Rationale for Combination

Biomarkers for Patient Selection

Cross-Linking to PD Mechanisms

See Also

Companies Developing Sigma-1 Agonists for PD

References

Related Hypotheses

💬 Discussion